{"links":{"html":"https://www.erudio.com/reports/keynote-975-nct04210115","json":"https://www.erudio.com/reports/keynote-975-nct04210115.json","markdown":"https://www.erudio.com/reports/keynote-975-nct04210115.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"keynote-975-04210115"}},"request":"https://www.erudio.com/contact?report=keynote-975-04210115"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":180,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":19,"optional":true,"price_per_verified_person_usd":15,"price_usd":285,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"keynote-975-nct04210115"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=keynote-975-04210115","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/keynote-975-nct04210115","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-18T22:07:59.892613Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: 17 sources cited (was 16); source breakdowns."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":2},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Event-free Survival (EFS)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":2,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: Number of participants with an adverse event (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Number of participants discontinuing study treatment due to an adverse event (AE)"},{"claim_count":21,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":3,"title":"Residual disease without surgery: additional systemic therapy, withholding and selective exceptions"},{"claim_count":21,"coverage":"discussed","id":"A2","source_count":3,"title":"Staging, airway invasion, referral and multidisciplinary suitability"},{"claim_count":35,"coverage":"discussed","id":"A3","source_count":1,"title":"CPS measurement, reporting and confidence near treatment thresholds"},{"claim_count":23,"coverage":"discussed","id":"A4","source_count":6,"title":"Who still receives dCRT amid perioperative and surgical alternatives?"},{"claim_count":15,"coverage":"discussed","id":"A5","source_count":2,"title":"Surgery omission, organ preservation and salvage-surgery trade-offs"},{"claim_count":18,"coverage":"discussed","id":"A6","source_count":3,"title":"Complete-response assessment and surveillance for nonoperative management"},{"claim_count":27,"coverage":"discussed","id":"A7","source_count":8,"title":"Research priorities, meaningful endpoints, feasibility and expectations"},{"claim_count":11,"coverage":"discussed","id":"A8","source_count":2,"title":"Radiation-dose debate and alternative chemoradiation backbones"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":11,"experience":16,"interpretation":15,"opinion":34,"primary_context":2,"question":20,"restatement":13,"uncertainty":18,"unspecified":51},"claims_by_kind":{"attributed_opinion":32,"interpretation":4,"limitation":5,"protocol_statement":1,"source_observation":138},"clinician_statements":80,"evidence_units":115,"findings":11,"organisational_accounts":1,"people_cited":23,"people_identity_verified":19,"people_total":24,"screened_sources":22,"verified_claims":180},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"registry":1}},"title":"Negative EFS announcements are consequential, but are not a complete results assessment"},{"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":2,"questions":5,"restated":5,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":23},"ma_question":true,"named_voices":2,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Routine post-chemoradiation nivolumab without surgery is questioned, with selective exceptions"},{"id":"F3","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":5,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":21},"ma_question":true,"named_voices":4,"passages":8,"sources":7,"sources_by_kind":{"media":7}},"title":"Histology drives expectations and challenges interpretation of pooled populations"},{"id":"F4","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":4,"questions":3,"restated":7,"views":6},"has_counterview":false,"limitations":2,"links":{"context":3,"support":23},"ma_question":true,"named_voices":3,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Staging errors can change the entire definitive-treatment decision"},{"id":"F5","structure":{"claims":36,"claims_by_group":{"comparisons":2,"experience":3,"questions":2,"restated":26,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":78},"ma_question":true,"named_voices":2,"passages":17,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"PD-L1 scoring concerns complicate confidence near treatment thresholds"},{"id":"F6","structure":{"claims":23,"claims_by_group":{"comparisons":3,"experience":1,"questions":5,"restated":6,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":26},"ma_question":true,"named_voices":5,"passages":13,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Perioperative advances narrow—but do not eliminate—the perceived role of dCRT"},{"id":"F7","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":0,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":15},"ma_question":true,"named_voices":6,"passages":14,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Organ preservation exposes a substantive dispute over surgery's value and burden"},{"id":"F8","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":6,"questions":6,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":19},"ma_question":true,"named_voices":7,"passages":16,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Nonoperative management depends on uncertain selection and nonuniform surveillance"},{"id":"F9","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Concurrent timing, chemotherapy restrictions and radiation dose shape interpretability"},{"id":"F10","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":2,"questions":5,"restated":5,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":20},"ma_question":true,"named_voices":10,"passages":16,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Research enthusiasm is qualified by endpoint priorities, feasibility and uncertain mechanisms of benefit"},{"id":"F11","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":1},"has_counterview":false,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":0,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Immune-toxicity vigilance qualifies enthusiasm for treatment intensification"}],"medical_affairs_question":"How should clinicians distinguish the announced EFS result from the still-uncertain post-chemoradiation choices for a nonsurgical patient with residual disease?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Negative EFS reports do not settle every immunotherapy decision"},{"id":"section-2","level":2,"title":"Withholding routine post-CRT treatment coexists with selective extrapolation"},{"id":"section-3","level":2,"title":"Histology separates systemic hope from local-response evidence"},{"id":"section-4","level":2,"title":"Staging determines whether the definitive-treatment question applies"},{"id":"section-5","level":2,"title":"CPS uncertainty is a clinical communication issue, not proof of trial assay failure"},{"id":"section-6","level":2,"title":"Perioperative advances leave a narrower but important dCRT population"},{"id":"section-7","level":2,"title":"Organ preservation raises a real dispute about surgery, not a settled replacement strategy"},{"id":"section-8","level":2,"title":"Observation requires selection tools and a follow-up strategy"},{"id":"section-9","level":2,"title":"Backbone, dose and sequencing criticisms should remain separate"},{"id":"section-10","level":2,"title":"Research proposals compete on endpoints and feasibility"},{"id":"section-11","level":2,"title":"Immune-toxicity vigilance limits uncomplicated intensification narratives"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3}],"id":"T1","label":"Primary endpoint: Event-free Survival (EFS)"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F10","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoint: Number of participants with an adverse event (AE)"},{"findings":[],"id":"T4","label":"Secondary endpoint: Number of participants discontinuing study treatment due to an adverse event (AE)"},{"findings":[{"id":"F3","shared_claims":10},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":6}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F9","shared_claims":2}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F9","shared_claims":1},{"id":"F11","shared_claims":8}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-18T22:07:59.892613Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-18T23:11:43Z","record_hash":"13e606308def1bf22da5f1a4a7aaed216c610dff71b39ea8fb5e420da2ac747a","release_hash":"4f7b7e8fa4f3db92ae461ad654665f6ebb48123a7afd2165ee0a42ca692b6504","report_id":"erudio-nct04210115","run_id":"9a4b34a1-29e6-43a4-8ff4-8428350dc201","schema_version":"5.0","slug":"keynote-975-04210115","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KEYNOTE-975 asks whether adding pembrolizumab to definitive chemoradiation improves outcomes in esophageal cancer treated without surgery. Clinicians in the sources reviewed question routine post-chemoradiation nivolumab and disagree over surgery’s role. Organ-preservation research attracts enthusiasm, while treatment timing and PD-L1 scoring draw scrutiny. Their commentary addresses negative EFS announcements, but a complete results assessment remains open. The trial’s main results are scheduled for ESMO 2026; this reflects commentary before that presentation.","meta_description":"22 sources screened · 180 verified statements (80 from clinicians verified by NPI or staff page) from 17 sources · 11 findings. Updated Oct 18, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-353186bdacd479edacc5"],"id":"F2","paraphrase":"A podcast moderator asked whether adjuvant nivolumab should be offered after neoadjuvant chemoradiation when a patient with initially resectable disease declines surgery or is judged surgically ineligible.","source_channel":"podcast","source_date":"2024-02-07","title":"Routine post-chemoradiation nivolumab without surgery is questioned, with selective exceptions"},{"cited_claim_ids":["claim-4a62817ffdd4734beadb","claim-fe949b57247f700d0940","claim-061d05acce0e4a7d739c"],"id":"F5","paraphrase":"A speaker in a YouTube discussion asked which tissue to use for PD-L1 CPS testing and whether testing should precede or follow therapy. Further questions addressed study-specific versus routine scorer training and when treatment could proceed without PD-L1 staining.","source_channel":"youtube","source_date":"2022-06-22","title":"PD-L1 scoring concerns complicate confidence near treatment thresholds"}]},"publication":{"approved_at":"2026-10-18T23:11:43Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-19T03:10:33Z","summary":"Report description rewritten to say where clinicians' views stand, not only what they discuss"},{"affected_ids":[],"date":"2026-10-19T03:10:49Z","summary":"taxonomy mapping corrected"},{"affected_ids":[],"date":"2026-10-27T19:26:46Z","summary":"Corrected to match the delivered report: the open question for Medical Affairs; 16 sources cited (was 17); 24 people found in the sources (was 25); 23 voices cited (was 24); 1 organisational or shared account (was 0); source breakdowns; the limitations; the sample findings; source quotations and links in the paid report."},{"affected_ids":[],"date":"2026-10-28T09:50:00Z","summary":"The trial is named KEYNOTE-975, as its sources and the report name it (was MK-3475-975/KEYNOTE-975)"},{"affected_ids":[],"date":"2026-10-28T13:00:25Z","summary":"Corrected to match the delivered report: 17 sources cited (was 16); source breakdowns."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","79 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed are not a representative sample of HCP opinion, and multiple formats of one discussion do not represent independent agreement.","Some potentially relevant posts and a video were unavailable to read. Parts of several long discussions were not completely assessed, so additional relevant opinions may be missing.","Several treatment, histology and safety comments cannot be reliably assigned to a named speaker. A program roster, institutional reference or professional identifier does not resolve that uncertainty.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The negative EFS statements relay sponsor announcements. No KEYNOTE-975 results publication, quantitative efficacy analysis, detailed subgroup analysis or comparative safety analysis is among the sources reviewed.","Earlier anticipatory comments and later announcement reactions come from different dates and contexts. Their sequence does not establish a change of mind or direct disagreement over detailed results.","Some transcript wording is unclear, including an overexpression qualifier in the adenocarcinoma discussion; the initial organ-preservation proposal is truncated.","Cross-disease analogies, other-study response figures, institutional experience and anecdotal tolerability observations are not KEYNOTE-975 outcomes.","No full protocol document or complete regulatory evidence is available here. Descriptions of prescribing labels and local treatment standards remain the contributors' accounts.","General CPS-scoring concerns do not establish inaccurate testing in KEYNOTE-975, and local historical reporting thresholds must not be substituted for trial criteria."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":4,"publication":0,"registry":1,"regulatory":0,"x_thread":7,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":16,"methods":1},"count":17,"evidence_window":{"end":"2026-10-16","start":"2022-06-22"},"retrieval_snapshot":"2026-10-18T11:06:10.058477Z","timeline":[{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W47"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":3,"week":"2026-W40"},{"count":1,"week":"2026-W42"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04210115:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04210115:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:33533655","quote_policy":"no_derivatives"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:362b41","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fe157","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:91b7d8","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f42d90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1377048372725624833:39a28401-d37b-4299-bbff-70898f9f6d9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1502071881855344650:6864e321-af63-4dbe-8063-688d3b9a1c9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1537223665745543169:153baa26-d7d8-4745-9622-e2d239c00f05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1638179910371135488:c8b62ba3-9115-4c56-805b-b401b393a8cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672245397681496065:2401d42b-7792-4efb-b487-d8cb8c7dd3ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1714417031435493840:0c8e02a7-6b1a-41f5-a221-de0c3a0adf1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049824836093125057:e45e72b3-b3d1-4f13-bdf0-d4ad32128831","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050241911160475759:208350ad-76ef-4ef7-a422-eb6edd21e103","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:b08afc32-8f0f-439e-8164-f5086c091554","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104356268454686951:b359d6e5-399d-40a5-8f52-05cb4f96eb63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105990928217334044:c005e9b7-687f-4ccb-8337-1162e1a8d6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:d02580f1-82d4-40a3-b92b-82849085c040","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111079668140900657:b2f67a8b-827c-42cd-a517-d6ee60e51885","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BZBokhX_eW4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ft-ih9xbsxA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NiedxmQiua4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:U7eFmld9eVg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZnOpPCU6VMw","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-10-16","start":"2021-03-31"},"retrieval_snapshot":"2026-10-18T11:06:10.058477Z","timeline":[{"count":1,"week":"2021-W13"},{"count":1,"week":"2022-W10"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W47"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":2,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"brand_names":["Fusilev","Khapzory"],"label":"levoleucovorin","slug":"levoleucovorin"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Esophageal squamous cell carcinoma","slug":"esophageal-squamous-cell-carcinoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Gastroesophageal junction cancer","slug":"gastroesophageal-junction-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Esophageal adenocarcinoma","slug":"esophageal-adenocarcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KEYNOTE-975","aliases":["KEYNOTE-975","Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)"],"brief_title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Esophageal Squamous Cell Carcinoma (ESCC)","Gastroesophageal Junction Carcinoma (GEJC)","Esophageal Adenocarcinoma (EAC)"],"enrollment":{"count":703,"type":"ACTUAL"},"interventions":[{"name":"pembrolizumab","synonyms":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"placebo","synonyms":["Normal saline solution"],"type":"DRUG"},{"name":"cisplatin","synonyms":["PLATINOL®"],"type":"DRUG"},{"name":"5-FU","synonyms":["ADRUCIL®"],"type":"DRUG"},{"name":"radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"leucovorin","synonyms":["calcium folinate","folinic acid"],"type":"DRUG"},{"name":"levoleucovorin","synonyms":["FUSILEV®","calcium levofolinate","levofolinic acid"],"type":"DRUG"},{"name":"oxaliplatin","synonyms":["ELOXATIN®"],"type":"DRUG"}],"nct_id":"NCT04210115","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2026-01-21","type":"ACTUAL"},"primary_endpoints":[{"description":"EFS is defined as the time from randomization to an event defined as local, regional, or distant radiological recurrence as assessed by the investigator; clinical recurrence as assessed by the investigator with histopathologic confirmation (in the absence of radiological disease recurrence by investigator assessment); or death from any cause, whichever occurs first.","measure":"Event-free Survival (EFS)","timeFrame":"Up to ~60 months"},{"description":"OS is defined as the time from randomization to death from any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to ~72 months"}],"registry_last_updated":"2026-07-22","registry_url":"https://clinicaltrials.gov/study/NCT04210115","short_name":"KEYNOTE-975","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2020-02-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"3475-975","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-3475-975","type":"other"},{"domain":"MSD","id":"KEYNOTE-975","type":"other"},{"domain":"PHRR","id":"PHRR200210-002490","type":"registry"},{"domain":"Japic-CTI","id":"205261","type":"registry"},{"domain":"EU CT","id":"2022-501531-16-00","type":"registry"},{"domain":"UTN","id":"U1111-1281-0822","type":"registry"},{"id":"2019-002006-51","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}